The global Allergy Immunotherapy Market is projected for substantial growth, from an estimated USD 3.7 billion in 2025 to USD 5 billion by 2035. This expansion reflects a Compound Annual Growth Rate (CAGR) of 3.5% over the forecast period, driven by the increasing global prevalence of allergic diseases and a strong push towards long-term desensitization therapies over symptomatic relief.
Market Dynamics: Innovation and Regulatory Support
The market’s growth is fueled by rising allergic disease prevalence and a shift towards long-term desensitization. Regulatory support in Europe and North America has expanded reimbursement for sublingual and subcutaneous immunotherapies, broadening patient access. Notably, the European Medicines Agency updated guidelines in 2024, streamlining approval for recombinant and peptide-based treatments. Investments in personalized allergy care and AI-powered allergen discovery are reshaping treatment. Thermo Fisher Scientific’s advancements in component-resolved diagnostics enable tailored immunotherapy. The World Allergy Organization emphasizes biologics and oral immunotherapy’s role in redefining treatment, especially for food-induced anaphylaxis. ALK-Abelló reports double-digit growth for sublingual immunotherapy tablets in Europe, driven by convenience and clinical success.
Click Here for More Information:- https://www.futuremarketinsights.com/reports/allergy-immunotherapy-market
Product and Immunotherapy Type Leaders
SLIT Tablets are expected to be the most lucrative product segment, reaching USD 2.1 billion by 2035 with a 4.2% CAGR, due to patient preference for non-invasive, self-administered treatment. Oral immunotherapy (OIT) is gaining momentum, particularly for pediatric food allergy management, projected to reach USD 1.2 billion by 2035 with a 4.5% CAGR. Injections (subcutaneous immunotherapy) remain widely used, maintaining steady growth at a 2.7% CAGR, reaching USD 1.4 billion by 2035, favored for long-term remission in specialty clinics. Sublingual Immunotherapy (SLIT) as an approach is projected to generate over USD 2.4 billion by 2035 with a 4.1% CAGR, driven by convenience and strong patient adherence.
Leading Indications and Allergen Types
Allergic Rhinitis remains the most dominant indication, with projected revenues surpassing USD 2.1 billion by 2035 (3.8% CAGR), benefiting from high global prevalence and convenient SLIT therapies. Food Allergy treatment is gaining traction, expected to grow at a 4.2% CAGR to reach USD 870 million by 2035, driven by increasing incidence, especially among children. Pollens are expected to remain the leading allergen type, with forecasted revenues of USD 1.7 billion by 2035 (3.7% CAGR), attributed to seasonal burdens and strong SLIT uptake. House Dust Mites (HDM) are projected to generate USD 1.1 billion (3.6% CAGR) due to chronic exposure.
Distribution Channels: Institutional vs. Retail
Institutional Sales are expected to remain the dominant distribution channel, projected to generate approximately USD 3.4 billion by 2035 (3.6% CAGR), supported by high-volume procurement through hospitals and specialized allergy clinics. Retail Sales are forecast to grow at a slightly faster CAGR of 3.9%, reaching USD 1.6 billion by 2035. This momentum is driven by rising consumer preference for convenience and access to over-the-counter or pharmacy-dispensed SLIT tablets, enhanced by digital pharmacies and direct-to-consumer models.
Key Regional Growth Trends
North America’s market is likely to grow at a 3.5% CAGR, underpinned by increasing diagnosis rates, favorable reimbursement, and innovation from biopharma companies. Germany (3.3% CAGR) and France (3.4% CAGR) are strongholds in Europe, supported by structured healthcare systems and broad reimbursement. Japan (3.5% CAGR) is advancing due to high allergic rhinitis prevalence and government support for SLIT. China (3.6% CAGR) is growing rapidly due to urbanization and pollution, with increasing support for immunotherapy. India (3.9% CAGR) represents a high-growth frontier with vast untapped potential, driven by urbanization and improving awareness.
Competitive Landscape and Strategic Collaborations
The allergy immunotherapy market is highly competitive, with key players like ALK-Abelló, Thermo Fisher Scientific, DBV Technologies, and Aimmune Therapeutics driving innovation. Technological progress focuses on improving safety, duration, and efficacy through AI integration and recombinant allergen platforms. Strategic collaborations between biotech firms and pharma majors are increasing, shifting the market towards precision-driven, scalable, and globally accessible care models.
Get Sample Report: – https://www.futuremarketinsights.com/reports/sample/rep-gb-9043
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
